Seven Institutional Players Moved ₹15.28 Crores Into Biotech on IPO Listing Day. Here’s Who They Are and What Their Track Records Say.
A QUESTION ON LISTING DAY
December 9, 2025. Neochem Bio Solutions debuts at ₹108—a solid 10% pop from its ₹98 IPO price. By mid-morning, the stock had already touched ₹113.40.
Most IPOs follow a familiar script: listing pop, retail investors chase, some volatility, then traders go home. But something different happened on Neochem’s listing day.
As the morning turned to afternoon, seven different institutional investors—each with their own track record, their own mandates, their own playbooks—independently decided to load up.
By close of business, they had quietly accumulated 1.42 million shares worth ₹15.28 crores.
Not in fanfare. Not with announcements. Just deliberate institutional buying on debut day.
Who were they? And more importantly—what does their presence tell us?
THE 67% CAGR FUND THAT DIDN’T EXIT
Finavenue Growth Fund – 249,600 shares @ ₹108
Imagine a fund that’s doubled your money in 2024. That’s not hyperbole. That’s Finavenue’s actual track record: 132% return in a single year.
Over two years, the fund has compounded at 67.70% CAGR—making it a top 5 AIF performer in 2024-25.
On Neochem’s opening day, Finavenue received an anchor allotment at ₹108. This is where the story gets interesting: as the stock jumped to ₹113.40 during the day—a 5.3% instant gain—the fund had a choice. Cash out instantly. Or hold.
Finavenue held.
A fund with 67.7% annual returns doesn’t chase quick 5% pops. That decision to hold suggests Finavenue’s portfolio managers saw something worth staying with.
Capital Deployed: ₹2.70 crores
THE CONTRARIAN WHO BOUGHT THE DIP
Neo Apex Venture LLP – 141,600 shares @ ₹105.31
Here’s where it gets sharper.
While most buyers were entering around ₹107-108, Neo Apex waited. The stock hit ₹113.40 in the morning. By afternoon, when it had pulled back and retail investors were getting nervous, Neo Apex entered at ₹105.31.
Lower price. Same conviction.
This matters because it tells us something about Neo Apex’s approach: they’re not following the crowd. They’re following the dip.
Who is Neo Apex? A venture capital partnership that’s built a 37.7% internal rate of return across its portfolio. Not 37.7% over five years. Not 37.7% on a single winner. That’s the average return across 25+ holdings.
Their portfolio includes holdings that returned +371% (RUCHISTRIP), +33.8% (NOIDATOLL), and +27.9% (PIGL). These aren’t one-off winners. They’re proof of a repeatable stock-picking process.
On Neochem’s listing day, Neo Apex deployed ₹1.49 crores at the exact moment when others were hesitating. That’s the move of a fund that knows what it’s doing.
Capital Deployed: ₹1.49 crores
THE IDENTICAL TWIN ENTRY
Mavira Growth Opportunities Fund – 249,600 shares @ ₹108
Here’s where it gets curious.
Mavira received an anchor allotment of exactly 249,600 shares at ₹108. The same quantity as Finavenue. The same price.
This isn’t coincidence. It’s how IPO anchor allocations work—the NSE standardizes allocations for funds fitting similar profiles. But the fact remains: two separate opportunity-focused funds, both micro-cap specialists, both got the same allocation and both held through opening day.
That’s a data point.
Capital Deployed: ₹2.70 crores
WHEN THE REAL ESTATE COMPANY SHOWS UP BIGGEST
Sheetal Sagar Builders & Developers – 368,400 shares @ ₹107.66
The largest single buyer among all seven was a real estate company.
Sheetal Sagar Builders deployed ₹3.97 crores—nearly three times what any other single fund committed. A construction company, on an IPO’s debut day, deciding biotech was worth the capital.
This isn’t a fund following a mandated growth strategy. This isn’t a quant algorithm firing off. This is a corporate treasurer making a deliberate portfolio move.
That ₹3.97 crores accumulated 368,400 shares—the most bought by any single entity that day. For a real estate company to show up this large on a biotech IPO’s debut tells us something: the cash was available, and the decision to deploy it was made.
Capital Deployed: ₹3.97 crores (Largest)
THE SUPPORTING CAST
SB Opportunities Fund I – 86,400 shares @ ₹108
An AIF specializing in identifying undervalued opportunities in niche sectors. No mega-capital, but participation nonetheless.
Capital Deployed: ₹0.93 crores
Pritesh Pravinchandra Vora (HNI) – 138,000 shares @ ₹107.41
A high net worth individual made a personal portfolio move into the stock on its debut day.
Capital Deployed: ₹1.48 crores
Ishaan Tradefin LLP – 187,200 shares @ ₹107.81
A trading and finance partnership participated in the opening day accumulation.
Capital Deployed: ₹2.02 crores
THE FULL PICTURE
Seven different entities. Seven different entry prices. Seven different capital bases. All moving in the same direction on the same day.
| Buyer | Shares | Entry Price | Amount |
|---|---|---|---|
| Finavenue (67.7% CAGR) | 249,600 | ₹108.00 | ₹2.70 Cr |
| Neo Apex (37.7% IRR) | 141,600 | ₹105.31 | ₹1.49 Cr |
| Mavira | 249,600 | ₹108.00 | ₹2.70 Cr |
| Sheetal Sagar | 368,400 | ₹107.66 | ₹3.97 Cr |
| SB Opportunities | 86,400 | ₹108.00 | ₹0.93 Cr |
| Pritesh Vora (HNI) | 138,000 | ₹107.41 | ₹1.48 Cr |
| Ishaan Tradefin | 187,200 | ₹107.81 | ₹2.02 Cr |
| TOTAL | 1.42M shares | Avg ₹107.56 | ₹15.28 Cr |
THE CONTEXT MATTERS
Neochem’s IPO wasn’t a quiet listing.
- QIB (Institutional) Subscription: 21.97x—meaning institutional money wanted in nearly 22 times over
- Total IPO Subscription: 15.52x
- Listing Day Opening: ₹108 (+10.2% from issue price)
- Intra-day High: ₹113.40 (+15.71%)
That kind of institutional demand on the IPO means serious money had been studying this company for weeks. They knew what was coming on debut day.
WHAT THIS ACTUALLY SAYS
On December 9, 2025, when Neochem’s shares hit the market:
- A fund manager with a proven ability to return 67.7% annually chose to hold rather than flip
- A venture capital firm with a 37.7% average return and a track record of picking winners bought on weakness
- Two micro-cap AIFs accumulated positions simultaneously
- A corporate treasury deployed nearly ₹4 crores into a biotech stock on its debut
- An individual investor and a trading firm also participated
₹15.28 crores deployed by seven different institutional players on a single IPO’s debut day.
This isn’t retail enthusiasm. This isn’t momentum chasing. This is institutional capital, guided by proven track records and seasoned decision-making processes, making deliberate moves on an IPO’s opening day.
Seven different players. Seven different reasons. One shared day.
Neochem Bio Solutions IPO listing: December 9, 2025
Institutional accumulation on day one: ₹15.28 crores across seven buyers
Track records: Finavenue (67.7% CAGR), Neo Apex (37.7% IRR), others with proven positioning strategies
Sources: NSE Bulk Deal Filings, Fund Performance Records, IPO Prospectus Data
Analysis Date: December 9, 2025
Not investment advice. Conduct independent due diligence.
Leave a Reply